Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway.
Pharmaceutical approval update.
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis.
A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
A phase II study of laquinimod in Crohn's disease.
Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis.
Glossopharyngeal neuralgia secondary to vascular compression in a patient with multiple sclerosis: a case report.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Metabolic features of the cell danger response.
Acorda Therapeutics announces positive AMPYRA® (dalfampridine) Phase 2 data in people with post-stroke deficits
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
Genmab announces details of planned ofatumumab Phase II study in multiple sclerosis
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Raloxifene Suppresses Experimental Autoimmune Encephalomyelitis and NF-κB-Dependent CCL20 Expression in Reactive Astrocytes.

Pages